Mednet Logo
HomeHematology
Hematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

How do you decide between blinatumomab or traditional chemotherapy in combination with TKI for upfront treatment of adult patients with Ph + ALL?

1
1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Washington

This question is likely inspired by the recent publication of a "chemotherapy-free induction and consolidation first-line treatment" for adults with Ph+ ALL (Foà et al., PMID 33085860; GIMEMA LAL2116). The authors reported relatively high rates of MRD- remissions by bone marrow BCR-ABL1 RT-PCR and i...

When testing for patients with symptoms of MPN, do you prefer to do JAK2 cascade testing or a leukemia NGS testing panel?

3 Answers

Mednet Member
Mednet Member
Hematology · Johns Hopkins University

Genetic testing with regard to the MPN can be usefully employed both diagnostically and prognostically. With respect to diagnosis, if an MPN is suspected based on symptoms such as aquagenic pruritis, ocular migraine, erythromelalgia, or the occurrence of an unexplained thrombosis, the first laborato...

Could patients with smIPI >1 and poor tolerability to R-CHOP be offered ISRT after 3 cycles of R-CHOP if interim PET showed 5-PS 1-3 response?

2
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University Medical Center

The revised NCCN guidelines largely reflect data from studies demonstrating excellent outcomes with four cycles of R-CHOP in patients with low-risk diffuse large B-cell lymphoma (DLBCL), including FLYER, LYSA/GOELAMS, SWOG S1001, and the most recent trial, LNH2009-1B. Although each of these trials e...

What is the utility of a hypercoagulability workup in recurrent cryptogenic stroke, and what specific tests would you recommend?

8
7 Answers

Mednet Member
Mednet Member
Neurology · University of Minnesota

Ambulatory monitoring for AFib is probably more helpful than such a thorough clotting workup.

If using the triplet AMPLIFY regimen with ven/acala/obin upfront, what do you then plan to use in 2nd line treatment of CLL?

2 Answers

Mednet Member
Mednet Member
Medical Oncology · Roswell Park Cancer Institute

For patients who achieve a favorable response that lasts >1 year (or so, this is a ballpark estimate that may shift with more data), I would be very comfortable re-treating with a covalent BTKi (preferably after screening for BTK resistance mutations by NGS where available - with note of caution tha...

Would you perform a bone marrow biopsy in a patient who had systemic anaphylaxis with hypotension to a stinging insect?

2
1 Answers

Mednet Member
Mednet Member
Allergy & Immunology · Emory University Hospital

I would start with checking a serum tryptase and D816V mutation. Also, apply a REMA score and do a good skin exam. With normal tryptase and copy number, still check for KIT mutation.

How do you manage perioperative anticoagulation for a patient with a history of recent, surgically provoked VTE?

1
1 Answers

Mednet Member
Mednet Member
Hematology · Medical University of South Carolina

In most cases, bridging is rarely indicated because the bleeding risk usually outweighs the risk of VTE recurrence during a short (1–2 day) interruption of anticoagulation. However, after a recent VTE (defined as <3 months), the estimated risk of VTE recurrence is high (>15–20% per year) (still low ...

How would you approach a patient with vitreoretinal lymphoma without CNS or systemic involvement?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University Medical Center

The optimal treatment approach for primary intraocular lymphoma is debated. This is a rare disease with only small retrospective series guiding therapy. There is no clear superior treatment approach in the literature. In clinical practice, younger patients are often treated initially with high-dose ...

Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?

5
2 Answers

Mednet Member
Mednet Member
Infectious Disease · Harbor - UCLA Medical Center

PCV-21 was recently approved by the FDA and supported by ACIP. At this early stage (August 2024), CDC has not finalized guidance on PCV-21, so we do not know how the vaccine schedule will be changed. An important distinction is that PCV-21 covers different serotypes of pneumococcus, as outlined in t...

When would you phlebotomize patients with secondary hemochromatosis, such as due to NAFLD/cirrhosis?

3
1 Answers

Mednet Member
Mednet Member
Hematology · Weill Cornell Medical College and Houston Methodist Hospital

My simple answer is “rarely, if ever” (but it can get much more complicated). Related to hepcidin changes, patients with chronic liver disease frequently have elevated serum ferritin and transferrin saturation, more so with alcoholic liver disease and non-alcoholic fatty liver disease. It is far fro...